...
首页> 外文期刊>臨床血液 >Philadelphia chromosome-positive acute lymphoblastic leukemia with monosomy 7 successfully treated with intermediate- and high-dose ara-C
【24h】

Philadelphia chromosome-positive acute lymphoblastic leukemia with monosomy 7 successfully treated with intermediate- and high-dose ara-C

机译:费城染色体阳性急性淋巴细胞白血病,用单体7用中间剂和高剂量ARA-C成功处理

获取原文
获取原文并翻译 | 示例
           

摘要

A 52-year-old man was admitted for treatment of acute lymphoblastic leukemia (ALL). The bone marrow was hypercellular with 67.2% blasts, which were negative for peroxidase, and expressed CD13, CD33, CD34, CD10 and CD7. Cytogenetic and molecular studies revealed t(9;22) and -7(Ph/-7) with major BCR/ABL rearrangement. The patient was treated with the L-AdVP regimen, but failed to achieve complete remission (CR). He then received two courses of chemotherapy consisting of intermediate- and high-dose cytarabine (ara-C), resulting in CR. This case suggests that Ph/-7 ALL with major BCR/ABL gene rearrangement showing coexpression of myeloid antigens may be sensitive to intermediate- and high-dose ara-C.
机译:一个52岁的男子被录取治疗急性淋巴细胞白血病(全部)。 骨髓具有67.2%的爆炸性,对过氧化物酶负阴性,表达CD13,CD33,CD34,CD10和CD7。 细胞遗传学和分子研究显示T(9; 22)和-7(pH / -7),具有主要的BCR / ABL重排。 用L-ADVP方案治疗患者,但未达到完全缓解(CR)。 然后他接受了两种由中间剂和高剂量的细胞酸(ARA-C)组化疗的疗程,导致Cr。 这种情况表明,具有主要BCR / ABL基因重新排列的pH / -7显示出显示骨髓抗原的共表达可以对中间剂和高剂量ARA-C敏感。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号